Multiple receptor tyrosine kinases regulate HIF-1α and HIF-2α in normoxia and hypoxia in neuroblastoma: Implications for antiangiogenic mechanisms of multikinase inhibitors

Oncogene

Volumn 29, Issue 20, 2010, Pages 2938-2949

  Nilsson, M B ^a   Zage, P E ^a   Zeng, L ^a   Xu, L ^a   Cascone, T ^a   Wu, H K ^a   Saigal, B ^a   Zweidler Mckay, P A ^a   Heymach, J V ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

HIF 1 ; HIF 2 ; Neuroblastoma; RTKs; Sorafenib; Sunitinib

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; MESSENGER RNA; PHOSPHOTRANSFERASE INHIBITOR; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN RET; PROTEIN TYROSINE KINASE; SORAFENIB; STEM CELL FACTOR; SUNITINIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG ACTIVITY; HUMAN; HUMAN CELL; HYPOXIA; MALE; MOUSE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN STABILITY; TUMOR CELL; TUMOR GROWTH; UPREGULATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANOXIA; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BLOTTING, WESTERN; CELL MOVEMENT; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOENZYME TECHNIQUES; INDOLES; MICE; MICE, INBRED NOD; MICE, SCID; NEOVASCULARIZATION, PATHOLOGIC; NEUROBLASTOMA; PROTO-ONCOGENE PROTEINS C-KIT; PROTO-ONCOGENE PROTEINS C-RET; PYRROLES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; RECEPTORS, INTERLEUKIN-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77952671059     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.60     Document Type: Article

References (49)

1. Beaudry P, Nilsson M, Rioth M, Prox D, Poon D, Xu L et al. (2008). Potent antitumor effects of ZD6474 on neuroblastoma via dual targeting of tumor cells and tumor endothelium. Mol Cancer Ther 7: 418-424. (Pubitemid 351302535)
2. Beppu K, Jaboine J, Merchant MS, Mackall CL, Thiele CJ. (2004). Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression. J Natl Cancer Inst 96: 46-55. (Pubitemid 38180959)
3. Bruns CJ, Solorzano CC, Harbison MT, Ozawa S, Tsan R, Fan D et al. (2000). Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 60: 2926-2935. (Pubitemid 30395817)
4. Canete A, Navarro S, Bermudez J, Pellin A, Castel V, Llombart-Bosch A. (2000). Angiogenesis in neuroblastoma: relationship to survival and other prognostic factors in a cohort of neuroblastoma patients. J Clin Oncol 18: 27-34. (Pubitemid 30036333)
5. Cohen PS, Chan JP, Lipkunskaya M, Biedler JL, Seeger RC. (1994). Expression of stem cell factor and c-kit in human neuroblastoma. The Children's Cancer Group. Blood 84: 3465-3472. (Pubitemid 24352911)
6. Das B, Yeger H, Tsuchida R, Torkin R, Gee MF, Thorner PS et al. (2005). A hypoxia-driven vascular endothelial growth factor/Flt1 autocrine loop interacts with hypoxia-inducible factor-1alpha through mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 pathway in neuroblastoma. Cancer Res 65: 7267-7275. (Pubitemid 41161258)
7. Donfrancesco A, Jenkner A, Castellano A, Ilari I, Milano GM, De Sio L et al. (2004). Ifosfamide/carboplatin/etoposide (ICE) as front-line, topotecan/cyclophosphamide as second-line and oral temozolomide as third-line treatment for advanced neuroblastoma over one year of age. Acta Paediatr Suppl 93: 6-11. (Pubitemid 38570249)
8. Eggert A, Ikegaki N, Kwiatkowski J, Zhao H, Brodeur GM, Himelstein BP. (2000). High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. Clin Cancer Res 6: 1900-1908. (Pubitemid 30305088)
9. Fakhari M, Pullirsch D, Paya K, Abraham D, Hofbauer R, Aharinejad S. (2002). Upregulation of vascular endothelial growth factor receptors is associated with advanced neuroblastoma. J Pediatr Surg 37: 582-587. (Pubitemid 34293096)
10. Hanahan D, Folkman J. (1996). Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364. (Pubitemid 26272076)
11. Hishiki T, Nimura Y, Isogai E, Kondo K, Ichimiya S, Nakamura Y et al. (1998). Glial cell line-derived neurotrophic factor/neurturin-induced differentiation and its enhancement by retinoic acid in primary human neuroblastomas expressing c-Ret, GFR alpha-1, and GFR alpha-2. Cancer Res 58: 2158-2165. (Pubitemid 28232902)
12. Holmquist-Mengelbier L, Fredlund E, Lofstedt T, Noguera R, Navarro S, Nilsson H et al. (2006). Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype. Cancer Cell 10: 413-423. (Pubitemid 44693470)
13. Kaipainen A, Korhonen J, Mustonen T, van Hinsbergh VW, Fang GH, Dumont D et al. (1995). Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endo-thelium during development. Proc Natl Acad Sci USA 92: 3566-3570.
14. Kane RC, Farrell AT, Madabushi R, Booth B, Chattopadhyay S, Sridhara R et al. (2009). Sorafenib for the treatment of unresectable hepatocellular carcinoma. Oncologist 14: 95-100.
15. Kaneko M, Tsuchida Y, Mugishima H, Ohnuma N, Yamamoto K, Kawa K et al. (2002). Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification. J Pediatr Hematol Oncol 24: 613-621. (Pubitemid 35285099)
16. Katzenstein HM, Salwen HR, Nguyen NN, Meitar D, Cohn SL. (2001). Antiangiogenic therapy inhibits human neuroblastoma growth. Med Pediatr Oncol 36: 190-193. (Pubitemid 32054389)
17. Kaushal V, Mukunyadzi P, Dennis RA, Siegel ER, Johnson DE, Kohli M. (2005). Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangio-genic markers is associated with advanced-stage disease. Clin Cancer Res 11: 584-593. (Pubitemid 40116883)
18. Kim WY, Perera S, Zhou B, Carretero J, Yeh JJ, Heathcote SA et al. (2009). HIF2alpha cooperates with RAS to promote lung tumor-igenesis in mice. J Clin Invest 119: 2160-2170.
19. Komuro H, Kaneko S, Kaneko M, Nakanishi Y. (2001). Expression of angiogenic factors and tumor progression in human neuroblastoma. J Cancer Res Clin Oncol 127: 739-743. (Pubitemid 33079374)
20. Kushner BH, Kramer K, Meyers PA, Wollner N, Cheung NK. (2000). Pilot study of topotecan and high-dose cyclophosphamide for resistant pediatric solid tumors. Med Pediatr Oncol 35: 468-474.
21. Ladenstein R, Philip T, Lasset C, Hartmann O, Garaventa A, Pinkerton R et al. (1998). Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry. J Clin Oncol 16: 953-965. (Pubitemid 28108728)
22. Langer I, Vertongen P, Perret J, Fontaine J, Atassi G, Robberecht P. (2000). Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in human neuroblastomas. Med Pediatr Oncol 34: 386-393. (Pubitemid 30346403)
23. Lesslie DP, Summy JM, Parikh NU, Fan F, Trevino JG, Sawyer TK et al. (2006). Vascular endothelial growth factor receptor-1 mediates migration of human colorectal carcinoma cells by activation of Src family kinases. Br J Cancer 94: 1710-1717. (Pubitemid 43924937)
24. Maris JM, Courtright J, Houghton PJ, Morton CL, Gorlick R, Kolb EA et al. (2008). Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program. Pediatr Blood Cancer 50: 581-587. (Pubitemid 351155829)
25. Maris JM, Hogarty MD, Bagatell R, Cohn SL. (2007). Neuroblasto-ma. Lancet 369: 2106-2120.
26. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK et al. (1999). Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid.Children's Cancer Group. N Engl J Med 341: 1165-1173.
27. Meister B, Grunebach F, Bautz F, Brugger W, Fink FM, Kanz L et al. (1999). Expression of vascular endothelial growth factor (VEGF) and its receptors in human neuroblastoma. Eur J Cancer 35: 445-449. (Pubitemid 29151943)
28. Meitar D, Crawford SE, Rademaker AW, Cohn SL. (1996). Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma. J Clin Oncol 14: 405-414. (Pubitemid 26051001)
29. Nakamura T, Ishizaka Y, Nagao M, Hara M, Ishikawa T. (1994). Expression of the ret proto-oncogene product in human normal and neoplastic tissues of neural crest origin. J Pathol 172: 255-260. (Pubitemid 24151976)
30. O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW et al. (2003). SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101: 3597-3605.
31. Peddinti R, Zeine R, Luca D, Seshadri R, Chlenski A, Cole K et al. (2007). Prominent microvascular proliferation in clinically aggressive neuroblastoma. Clin Cancer Res 13: 3499-3506. (Pubitemid 46955109)
32. Peng XH, Karna P, Cao Z, Jiang BH, Zhou M, Yang L. (2006). Crosstalk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression. J Biol Chem 281: 25903-25914. (Pubitemid 44401796)
33. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM. (2003). Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3: 347-361. (Pubitemid 38340304)
34. Phillips RJ, Mestas J, Gharaee-Kermani M, Burdick MD, Sica A, Belperio JA et al. (2005). Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1alpha. J Biol Chem 280: 22473-22481. (Pubitemid 40827903)
35. Pickering LM, Pyle L, Larkin JM. (2009). Sunitinib is superior to interferon alpha with respect to quality of life for patients with renal cell carcinoma. Nat Clin Pract Oncol 6: 6-7.
36. Richardson DS, Lai AZ, Mulligan LM. (2006). RET ligand-induced internalization and its consequences for downstream signaling. Oncogene 25: 3206-3211.
37. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A et al. (2006). Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355: 2542-2550. (Pubitemid 44917502)
38. Semenza GL. (2003). Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732.
39. Shusterman S, Maris JM. (2005). Prospects for therapeutic inhibition of neuroblastoma angiogenesis. Cancer Lett 228: 171-179. (Pubitemid 41188439)
40. Stommel JM, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH, Wiedemeyer R et al. (2007). Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318: 287-290. (Pubitemid 47574858)
41. Wey JS, Fan F, Gray MJ, Bauer TW, McCarty MF, Somcio R et al. (2005). Vascular endothelial growth factor receptor-1 promotes migration and invasion in pancreatic carcinoma cell lines. Cancer 104: 427-438. (Pubitemid 40993273)
42. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H et al. (2004). BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64: 7099-7109. (Pubitemid 39331023)
43. Witte D, Thomas A, Ali N, Carlson N, Younes M. (2002). Expression of the vascular endothelial growth factor receptor-3 (VEGFR-3) and its ligand VEGF-C in human colorectal adenocarcinoma. Anticancer Res 22: 1463-1466. (Pubitemid 34839151)
44. Yamagata K, Tagami M, Ikeda K, Tsumagari S, Yamori Y, Nara Y. (2002). Differential regulation of glial cell line-derived neurotrophic factor (GDNF) mRNA expression during hypoxia and reoxygena-tion in astrocytes isolated from stroke-prone spontaneously hypertensive rats. Glia 37: 1-7. (Pubitemid 34103089)
45. Yang AD, Camp ER, Fan F, Shen L, Gray MJ, Liu W et al. (2006). Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in human pancreatic carcinoma cells. Cancer Res 66: 46-51. (Pubitemid 43166007)
46. Yang JC. (2004). Bevacizumab for patients with metastatic renal cancer: an update. Clin Cancer Res 10: 6367S-6370S. (Pubitemid 39287493)
47. Yoshida D, Kim K, Noha M, Teramoto A. (2006). Hypoxia inducible factor 1-alpha regulates of platelet derived growth factor-B in human glioblastoma cells. J Neurooncol 76: 13-21. (Pubitemid 43115754)
48. Zhang L, Smith KM, Chong AL, Stempak D, Yeger H, Marrano P et al. (2009). in vivo antitumor and antimetastatic activity of sunitinib in preclinical neuroblastoma mouse model. Neoplasia 11: 426-435.
49. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM et al. (2000). Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 60: 1541-1545. (Pubitemid 30183422)